Piper Sandler Initiates Coverage on Palisade Bio (NASDAQ:PALI)

Stock analysts at Piper Sandler assumed coverage on shares of Palisade Bio (NASDAQ:PALI) in a research report issued on Monday, MarketBeat reports. The firm set an “overweight” rating and a $25.00 price target on the stock.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Palisade Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “buy” rating on shares of Palisade Bio in a report on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Palisade Bio has an average rating of “Moderate Buy” and an average target price of $20.50.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $2.36 on Monday. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.64. The company has a market capitalization of $351.64 million, a price-to-earnings ratio of -1.11 and a beta of 1.54. The business has a 50-day moving average of $1.97 and a 200-day moving average of $1.29.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.06). Research analysts expect that Palisade Bio will post -12.43 EPS for the current fiscal year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.